Tutorial
RH CHAIN
…
Wallet
Overview
Follow the Money
Daily Brief
Live
Congress
Corporate Insiders
Government Money
Political Influence
Institutions
Washington Network
Follow the Power
Disclosure Clock
AI Investigator
Watchlist
Convergence
INSIDER Alpha
Signal ledger
Historical Replay
Robinhood Chain
Proof
Trading
Token
Pro
Account
Methodology
Match review
Launch readiness
Tutorial
01
Overview
02
Follow the Money
03
Daily Brief
04
Live
05
Congress
06
Corporate Insiders
07
Government Money
08
Political Influence
09
Institutions
10
Washington Network
11
Follow the Power
12
Disclosure Clock
13
AI Investigator
14
Watchlist
Convergence
INSIDER Alpha
Signal ledger
Historical Replay
Robinhood Chain
Proof
Trading
Token
Pro
Account
Methodology
Match review
Launch readiness
Overview
Follow the Money
Daily Brief
Live
Congress
Corporate Insiders
Government Money
Political Influence
Institutions
Washington Network
Follow the Power
Disclosure Clock
AI Investigator
Watchlist
Convergence
INSIDER Alpha
Signal ledger
Historical Replay
Robinhood Chain
Proof
Trading
Token
Pro
Account
Methodology
Match review
Launch readiness
Tutorial
Data sources
SEC FORM 4
2h ago
HOUSE PTR
2h ago
SEC 13F
2h ago
ROBINHOOD CHAIN
2h ago
Public company
NVS
NOVARTIS AG
CIK 0001114448
EDGAR filings
Open in network
○
Watch NVS
Disclosed transactions
1
Buys / sells
0 / 1
Max Insider Score
24
Connections
12
with evidence
NVS · disclosed activity on price
Disclosed transactions
Score
Actor
Security
Side
Value
Executed
Disclosed
Lag
Source
Evidence
24
Kevin Hern
R
Self
NVS
NOVARTIS AG
Sale
SELL
$15K – $50K
Aug 27, 2026
Sep 25, 2026
traded Aug 27, 2026
+29d
HOUSE PTR
Evidence
Evidence
Close
Verified connections
In industry
evidence
Pharmaceuticals, devices & health services
SEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
← Connected organization
evidence
NOVARTIS CORPORATION POLITICAL ACTION COMMITTEE
FEC Form 1 connected organization: NOVARTIS CORPORATION (curated map) · Nov 4, 2026
← Disclosed trade in
evidence
Kevin Hern
Sale disclosed 2026-09-25 · Sep 25, 2026
← Lobbied for
evidence
BGR GOVERNMENT AFFAIRS
LDA Q2 2026 second quarter · Health issues, Medicare/Medicaid · Aug 26, 2026
← Lobbied for
evidence
FORBES-TATE
LDA Q1 2026 first quarter · Taxation, Health issues, Medicare/Medicaid, Trade, Budget/appropriations, Copyright/patent · Aug 26, 2026
← Lobbied for
evidence
TARPLIN, DOWNS & YOUNG, LLC
LDA Q2 2026 second quarter · Medicare/Medicaid, Trade, Budget/appropriations, Health issues · Aug 26, 2026
← Lobbied for
evidence
MONUMENT ADVOCACY
LDA Q2 2026 second quarter · Health issues, Trade, Taxation · Aug 26, 2026
← Lobbied for
evidence
TODD STRATEGY GROUP
LDA Q1 2026 first quarter · Health issues, Medicare/Medicaid, Trade · Aug 26, 2026
← Lobbied for
evidence
DLA PIPER LLP (US)
LDA Q1 2026 first quarter · Copyright/patent, Taxation, Trade, Health issues, Medicare/Medicaid · Aug 26, 2026
← Lobbied for
evidence
BROWNSTEIN HYATT FARBER SCHRECK, LLP
LDA Q1 2026 first quarter · Health issues · Aug 26, 2026
← Lobbied for
evidence
TIBER CREEK HEALTH STRATEGIES, INC.
LDA Q2Y 2026 second quarter · issues not listed · Aug 26, 2026
← Lobbied for
evidence
CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS
LDA Q2 2026 second quarter · Trade, Health issues · Aug 26, 2026
Lobbying
$5.34M reported · de-duplicated
2026 Q2
$1.41M
in-house
2026 Q1
$3.93M
in-house
CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS
$50K
2026 Q1 · posted Aug 26, 2026 · Trade, Health issues
TIBER CREEK HEALTH STRATEGIES, INC.
$60K
2026 Q1 · posted Aug 26, 2026 ·
TARPLIN, DOWNS & YOUNG, LLC
$60K
2026 Q1 · posted Aug 26, 2026 · Budget/appropriations, Health issues, Medicare/Medicaid, Trade
FORBES-TATE
$50K
2026 Q1 · posted Aug 26, 2026 · Taxation, Health issues, Medicare/Medicaid, Trade, Budget/appropriations, Copyright/patent
In-house report
$3.93M
2026 Q1 · posted Aug 26, 2026 · Labor, Budget/appropriations, Copyright/patent, Health issues, Medicare/Medicaid, Taxation, Trade
TARPLIN, DOWNS & YOUNG, LLC
$60K
2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid, Trade, Budget/appropriations, Health issues
TODD STRATEGY GROUP
$60K
2026 Q2 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid, Trade
DLA PIPER LLP (US)
$60K
2026 Q2 · posted Aug 26, 2026 · Copyright/patent, Taxation, Trade, Health issues, Medicare/Medicaid
In-house report
$1.41M
2026 Q2 · posted Aug 26, 2026 · Budget/appropriations, Copyright/patent, Health issues, Medicare/Medicaid, Taxation, Trade, Labor
TODD STRATEGY GROUP
$60K
2026 Q1 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid, Trade
TIBER CREEK HEALTH STRATEGIES, INC.
$60K
2026 Q2 · posted Aug 26, 2026 ·
FORBES-TATE
$50K
2026 Q2 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid, Trade, Budget/appropriations, Copyright/patent, Taxation
Connected PAC contributions
FEC · direct to members
Donald G. Davis
D
$10K
NOVARTIS CORPORATION POLITICAL ACTION COMMITTEE
Brett Guthrie
R
$10K
NOVARTIS CORPORATION POLITICAL ACTION COMMITTEE
John Joyce
R
$10K
NOVARTIS CORPORATION POLITICAL ACTION COMMITTEE
Scott H. Peters
D
$9,000
NOVARTIS CORPORATION POLITICAL ACTION COMMITTEE
Richard Hudson
R
$8,500
NOVARTIS CORPORATION POLITICAL ACTION COMMITTEE
Brittany Pettersen
D
$8,000
NOVARTIS CORPORATION POLITICAL ACTION COMMITTEE
Kevin Mullin
D
$7,000
NOVARTIS CORPORATION POLITICAL ACTION COMMITTEE
Martin Heinrich
D
$6,000
NOVARTIS CORPORATION POLITICAL ACTION COMMITTEE
Gabe Amo
D
$6,000
NOVARTIS CORPORATION POLITICAL ACTION COMMITTEE
Rudy Yakym III
R
$6,000
NOVARTIS CORPORATION POLITICAL ACTION COMMITTEE
Lori Trahan
D
$5,500
NOVARTIS CORPORATION POLITICAL ACTION COMMITTEE
Katherine M. Clark
D
$5,500
NOVARTIS CORPORATION POLITICAL ACTION COMMITTEE